Survodutide vs Syn-Ake
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Syn-Ake
Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide that mimics the effect of Waglerin-1, a peptide found in Temple Viper venom. It's used in cosmetics for anti-wrinkle effects.
Full details →Side-by-Side Comparison
| Aspect | Survodutide | Syn-Ake |
|---|---|---|
| Mechanism | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. | Acts as a competitive antagonist at the nicotinic acetylcholine receptor, reducing muscle contractions similar to Botox but through a different mechanism. Provides muscle-relaxing effects when applied topically. |
| Typical Dosage | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. | Topical: 1-4% concentration in serums or creams. Applied 1-2 times daily to target areas like forehead and crow's feet. |
| Administration | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. | Topical application only. Should be applied to clean skin. Often combined with other anti-aging peptides for synergistic effects. |
| Side Effects | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. | Generally well-tolerated topically. Rare reports of mild skin irritation or sensitivity. |
| Best For |
Key Differences
Unique to Survodutide:
Unique to Syn-Ake:
Detailed Analysis
Commonalities
Survodutide and Syn-Ake are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Survodutide for Weight Loss, Liver Health. Choose Syn-Ake for Skin Health & Aesthetics.
Ready to Learn More?
Looking for trusted sources?